Trial
NCT04702425
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Non-Hodgkin Lymphoma (NHL)
Intervention
VOB560
Why stopped
Business reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-10